Neuroendocrine tumors of the gastro-entero-pancreatic system

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

596

HTML

5158

Tables (1-5)

270

Sum=6024

Sep 21, 2008 (publication date) through Jan 30, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 21, 2008; 14(35): 5377-5384
Published online Sep 21, 2008. doi: 10.3748/wjg.14.5377

Table 5 Results of studies of molecularly targeted agents in patients with neuroendocrine tumours[54,55]

Agent	Response rate (%)	PFS rate (%)/Duration
VEGF monoclonal antibody
Bevacizumab[56]	18	95 at 18 wk
mTOR inhibitor
RAD001 (everolimus)	13	71 at 24 wk
Temsirolimus[57]	5.6	50 at 6 mo
VEGF TKI
Sunitinib	10	Median, 42 wk
Vatalanib	In progress	(time to progression)
Sorafenib	In progress
Pazopanib	In progress
PDGFR/Kit/Abl inhibitor
Imatinib[58]	4	Median, 5.9 mo
EGFR inhibitor
Gefitinib	4	61 (carcinoids) and 31 (pancreatic tumor) at 6 mo
Other
Bortezomib[59]	0	Median, 3 mo
		(Time to treatment failure)

PFS: Progression free survival.

Citation: Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008; 14(35): 5377-5384
URL: https://www.wjgnet.com/1007-9327/full/v14/i35/5377.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5377